583 related articles for article (PubMed ID: 24618042)
1. Clinical utility of natural killer cells in cancer therapy and transplantation.
Knorr DA; Bachanova V; Verneris MR; Miller JS
Semin Immunol; 2014 Apr; 26(2):161-72. PubMed ID: 24618042
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic applications: natural killer cells in the clinic.
Miller JS
Hematology Am Soc Hematol Educ Program; 2013; 2013():247-53. PubMed ID: 24319187
[TBL] [Abstract][Full Text] [Related]
3. NK cells in therapy of cancer.
Bachanova V; Miller JS
Crit Rev Oncog; 2014; 19(1-2):133-41. PubMed ID: 24941379
[TBL] [Abstract][Full Text] [Related]
4. Challenges of cancer therapy with natural killer cells.
Klingemann H
Cytotherapy; 2015 Mar; 17(3):245-9. PubMed ID: 25533934
[TBL] [Abstract][Full Text] [Related]
5. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
7. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM; Becker-Hapak M; Cashen AF; Jacobs M; Wong P; Foster M; McClain E; Desai S; Pence P; Cooley S; Brunstein C; Gao F; Abboud CN; Uy GL; Westervelt P; Jacoby MA; Pusic I; Stockerl-Goldstein KE; Schroeder MA; DiPersio JF; Soon-Shiong P; Miller JS; Fehniger TA
Blood; 2022 Feb; 139(8):1177-1183. PubMed ID: 34797911
[TBL] [Abstract][Full Text] [Related]
8. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cells in the treatment of high-risk acute leukaemia.
Locatelli F; Moretta F; Brescia L; Merli P
Semin Immunol; 2014 Apr; 26(2):173-9. PubMed ID: 24613727
[TBL] [Abstract][Full Text] [Related]
10. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
[TBL] [Abstract][Full Text] [Related]
11. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS
Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021
[TBL] [Abstract][Full Text] [Related]
12. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
[TBL] [Abstract][Full Text] [Related]
13. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
[TBL] [Abstract][Full Text] [Related]
15. Successful Transfer of Umbilical Cord Blood CD34
Dolstra H; Roeven MWH; Spanholtz J; Hangalapura BN; Tordoir M; Maas F; Leenders M; Bohme F; Kok N; Trilsbeek C; Paardekooper J; van der Waart AB; Westerweel PE; Snijders TJF; Cornelissen J; Bos G; Pruijt HFM; de Graaf AO; van der Reijden BA; Jansen JH; van der Meer A; Huls G; Cany J; Preijers F; Blijlevens NMA; Schaap NM
Clin Cancer Res; 2017 Aug; 23(15):4107-4118. PubMed ID: 28280089
[No Abstract] [Full Text] [Related]
16. Natural killer cell receptors: alterations and therapeutic targeting in malignancies.
Konjević G; Vuletić A; Mirjačić Martinović K
Immunol Res; 2016 Feb; 64(1):25-35. PubMed ID: 26374324
[TBL] [Abstract][Full Text] [Related]
17. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
[TBL] [Abstract][Full Text] [Related]
18. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
[TBL] [Abstract][Full Text] [Related]
19. Expanded and armed natural killer cells for cancer treatment.
Shimasaki N; Coustan-Smith E; Kamiya T; Campana D
Cytotherapy; 2016 Nov; 18(11):1422-1434. PubMed ID: 27497701
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
